10214-84-3

Basic information

• Product Name: N-[2-(3,4-dimethoxyphenyl)ethyl]-2-(4-hydroxyphenyl)acetamide
• CAS NO: 10214-84-3
• Molecular Formula: C₁₈H₂₁NO₄
• Molecular Weight: 315.3636
• Mol File: 10214-84-3.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 566.2°C at 760 mmHg
• Flash Point: 296.2°C
• Density: 1.175g/cm³
• Vapor Pressure: 2.01E-13mmHg at 25°C
• Refractive Index: 1.572
• CAS DataBase Reference: N-[2-(3,4-dimethoxyphenyl)ethyl]-2-(4-hydroxyphenyl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[2-(3,4-dimethoxyphenyl)ethyl]-2-(4-hydroxyphenyl)acetamide(10214-84-3)
• EPA Substance Registry System: N-[2-(3,4-dimethoxyphenyl)ethyl]-2-(4-hydroxyphenyl)acetamide(10214-84-3)

Safety Data

• Hazardous Substances Data: 10214-84-3(Hazardous Substances Data)

Upstream product

• 156-38-7 4-hydroxyphenylacetate 
• 120-20-7 2-(3,4-dimethoxyphenyl)-ethylamine 
• 14199-15-6 Methyl 4-hydroxyphenylacetate 

Downstream Products

• 52358-58-4 (+/-)-3α,15,16-trimethoxy-8-oxo-Δ^1,6-erythrinan 
• 3195-01-5 L-(-)-N-norarmepavine 
• 1609169-63-2 tert-butyl 1-(4-((5-bromopentyl)oxy)benzyl)-6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1609169-62-1 tert-butyl 1-(4-(4-bromobutoxy)benzyl)-6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1609169-61-0 tert-butyl 1-(4-(3-bromopropoxy)benzyl)-6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1609169-60-9 tert-butyl 1-(4-hydroxybenzyl)-6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1609169-53-0 6,7-dimethoxy-1-(4-((6-(4-phenylpiperidin-1-yl)hexyl)oxy)benzyl)-1,2,3,4-tetrahydroisoquinoline 
• 1609169-59-6 tert-butyl 1-(4-(benzyloxy)benzyl)-6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1609169-52-9 1-(4-((6-(4-benzylpiperazin-1-yl)hexyl)oxy)benzyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline 
• 1609169-51-8 6,7-dimethoxy-1-(4-((6-(4-phenylpiperazin-1-yl)hexyl)oxy)benzyl)-1,2,3,4-tetrahydroisoquinoline 
• 1609169-50-7 4-benzyl-1-(6-(4-((6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)phenoxy)hexyl)piperidin-4-ol 
• 1609169-49-4 4-(6-(4-((6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)phenoxy)hexyl)morpholine 
• 1609169-48-3 1-(6-(4-((6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)phenoxy)hexyl)piperidin-4-ol 
• 1609169-47-2 6,7-dimethoxy-1-(4-((6-(pyrrolidin-1-yl)hexyl)oxy)benzyl)-1,2,3,4-tetrahydroisoquinoline 

Relevant articles and documents

Synthesis of the erythrina alkaloid erysotramidine

A concise synthesis of erysotramidine (an alkaloid belonging to the erythrina family) was achieved starting with an inexpensive phenol and amine derivative. The synthesis is based on oxidative phenol dearomatizations mediated by a hypervalent iodine reage

Synthesis and biological evaluation of novel gigantol derivatives as potential agents in prevention of diabetic cataract

As a continuation of our efforts directed towards the development of natural anti-diabetic cataract agents, gigantol was isolated from Herba dendrobii and was found to inhibit both aldose reductase (AR) and inducible nitric oxide synthase (iNOS) activity, which play a significant role in the development and progression of diabetic cataracts. To improve its bioefficacy and facilitate use as a therapeutic agent, gigantol (compound 14f) and a series of novel analogs were designed and synthesized. Analogs were formulated to have different substituents on the phenyl ring (compounds 4, 5, 8, 14a-e), substitute the phenyl ring with a larger steric hindrance ring (compounds 10, 17c) or modify the carbon chain (compounds 17a, 17b, 21, 23, 25). All of the analogs were tested for their effect on AR and iNOS activities and on D-galactose-induced apoptosis in cultured human lens epithelial cells. Compounds 5, 10, 14a, 14b, 14d, 14e, 14f, 17b, 17c, 23, and 25 inhibited AR activity, with IC50 values ranging from 5.02 to 288.8 μM. Compounds 5, 10, 14b, and 14f inhibited iNOS activity with IC50 ranging from 432.6 to 1188.7 μM. Compounds 5, 8, 10, 14b, 14f, and 17c protected the cells from D-galactose induced apoptosis with viability ranging from 55.2 to 76.26%. Of gigantol and its analogs, compound 10 showed the greatest bioefficacy and is warranted to be developed as a therapeutic agent for diabetic cataracts.

Design, synthesis and biological evaluation of benzylisoquinoline derivatives as multifunctional agents against Alzheimer's disease

A novel series of benzylisoquinoline derivatives were designed, synthesized, and evaluated as multifunctional agents against Alzheimer's disease (AD). The screening results showed that most of the compounds significantly inhibited cholinesterases (ChEs),